Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China

Background and Aims: Ravidasvir (RDV) is a new generation pangenotypic hepatitis C virus (HCV) NS5A inhibitor, with high barrier to baseline resistance-associated species. This is the first phase 2/3 study conducted in Mainland China confirming the efficacy and safety of RDV + ritonavir-boosted dano...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xiaoyuan, Feng, Bo, Guan, Yujuan, Zheng, Sujun, Sheng, Jifang, Yang, Xingxiang, Ma, Yuanji, Huang, Yan, Kang, Yi, Wen, Xiaofeng, Li, Jun, Tan, Youwen, He, Qing, Xie, Qing, Wang, Maorong, An, Ping, Gong, Guozhong, Liu, Huimin, Ning, Qin, Hua, Rui, Ning, Bo, Xie, Wen, Zhang, Jiming, Huang, Wenxiang, Yang, Yongfeng, Lin, Minghua, Zhao, Yingren, Yu, Yanhong, Jia, Jidong, Yang, Dongliang, Chen, Liang, Ye, Yinong, Nan, Yuemin, Gong, Zuojiong, Zhang, Quan, Hu, Peng, Wang, Fusheng, Li, Yongguo, Li, Dongliang, Jia, Zhansheng, Hou, Jinlin, Chen, Chengwei, Wu, Jinzi J., Wei, Lai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783683/
https://www.ncbi.nlm.nih.gov/pubmed/31608212
http://dx.doi.org/10.14218/JCTH.2019.00033

Ejemplares similares

Ejemplares similares